Results
The model showed that MS for treating pediatric patient with acute
asthma, was associated with lower total cost than standard therapy (US
$1149 vs US $1598 average cost per patient), and higher QALYs ( 0.60
vs 0.52 average per patient); showing dominance. A position of dominance
negates the need to calculate an incremental cost-effectiveness ratio
(Table 3 ).